April 8 (Reuters) - Poxel SA POXEL.PA :
* POXEL ANNOUNCES FIRST QUARTER 2019 FINANCIAL UPDATE
* Q1 REVENUE EUR 14.9 MILLION VERSUS EUR 18.3 MILLION YEAR AGO
* THIS YEAR WILL BE VERY IMPORTANT FOR POXEL-CEO
* Q1 CASH AND CASH EQUIVALENTS EUR 59.0 MILLION VERSUS EUR 66.7 MILLION IN
Q4 2018
* THERE WILL BE SEVERAL SIGNIFICANT MILESTONES THAT HAVE POTENTIAL FOR
SUBSTANTIAL
VALUE CREATION-CEO
* WE PLAN TO INITIATE A PIVOTAL PHASE 2 PROGRAM IN BIOPSY-PROVEN NASH
PATIENTS IN
THE FOURTH QUARTER OR EARLY 2020
* FOR PXL065, DURING Q2 2019, PLANS TO INITIATE THE PHASE 1B MULTIPLE
ASCENDING
DOSE STUDY, RESULTS EXPECTED DURING Q3 2019
Source text for Eikon: ID:nBw5gf3Lka
Further company coverage: POXEL.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))